Compare Alibaba Group (BABA) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs BioNano Genomics Inc — how do they compare? Alibaba Group trades at $124.71 (market cap $308.93B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Alibaba Group is far larger — about 22615.7× BioNano Genomics Inc's market cap, and Alibaba Group pays a 0.82% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BABA | BNGO | |
|---|---|---|
Market Cap | $308.93B | $13.66M |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $4.92 |
52-Week Low | $94.83 | $1.06 |
Enterprise Value | $303.72B | $16.26M |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $124.27, down 6.08% in the past 24 hours, amid a wave of class-action lawsuits alleging securities fraud. The stock shows a bullish technical signal with support near $126, but recent earnings misses and a negative net cash flow of $97.16 billion in 2025 highlight operational challenges. Revenue grew to $996.35 billion in 2025, with a net income margin of 13.05%, though profitability is pressured by high investing outflows.
The outlook is clouded by legal risks and earnings volatility, but analyst consensus remains bullish with a $195 price target, suggesting 57% upside. Key risks include regulatory scrutiny in China and competitive pressures, while the dividend of $1.05 per share offers income support. Investors should weigh strong fundamentals against near-term headwinds.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
